{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T13:05:42Z","timestamp":1767359142103,"version":"3.48.0"},"reference-count":49,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["Indian J Dermatol Venereol Leprol"],"abstract":"<jats:p>Chimeric antigen receptor (CAR) T-cells are autologous T-cells genetically engineered to express an antigen receptor that can recognise and kill cells expressing that target antigen. Originally developed for refractory or relapsed B-cell and plasma cell malignancies, CAR T-cell therapy is now being explored as a promising treatment for B-cell\u2013mediated autoimmune diseases. CAR-T cells produce \u2018deep\u2019 B-cell depletion and cause \u2018resetting\u2019 of the immune system, thereby achieving long-lasting remissions and potentially even \u2018cure\u2019, addressing some major limitations of current immunosuppressive and biological therapies. This narrative review discusses the current status of CAR T-cell therapy, along with its potential future applications, for dermatological disorders.<\/jats:p>","DOI":"10.25259\/ijdvl_1877_2025","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T13:02:08Z","timestamp":1767358928000},"page":"52-59","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chimeric antigen receptor (CAR) T-cell therapy in dermatology: A narrative review"],"prefix":"10.25259","volume":"92","author":[{"given":"Shreya K","family":"Gowda","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology, All India Institute of  Medical Sciences, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonali","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, All India Institute of  Medical Sciences, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaushal K","family":"Verma","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, All India Institute of  Medical Sciences, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishal","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, All India Institute of  Medical Sciences, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"10.25259\/IJDVL_1877_2025\/ref-1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000500488","article-title":"Chimeric antigen receptor T-cell therapy: Reach to solid tumor experience","volume":"97","author":"Metzinger","year":"2019","journal-title":"Oncology"},{"key":"10.25259\/IJDVL_1877_2025\/ref-2","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s11427-022-2212-5","article-title":"CARs: A new approach for the treatment of autoimmune diseases","volume":"66","author":"Sun","year":"2023","journal-title":"Sci China Life Sci"},{"key":"10.25259\/IJDVL_1877_2025\/ref-3","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.25259\/IJDVL_1877_2025\/ref-4","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: Design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"10.25259\/IJDVL_1877_2025\/ref-5","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: The evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature"},{"key":"10.25259\/IJDVL_1877_2025\/ref-6","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.tracli.2023.05.001","article-title":"CAR-T cell therapy in India: Challenges and opportunities for advancement","volume":"30","author":"Kumar Suvvari","year":"2023","journal-title":"Transfus Clin Biol"},{"key":"10.25259\/IJDVL_1877_2025\/ref-8","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1111\/jdv.16752","article-title":"Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European academy of dermatology and venereology (EADV)","volume":"34","author":"Joly","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_1877_2025\/ref-9","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1111\/jdv.16561","article-title":"Long-term outcomes of rituximab therapy in pemphigus","volume":"34","author":"Shimanovich","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_1877_2025\/ref-10","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1001\/jamadermatol.2023.5679","article-title":"Sustained remission without corticosteroids among patients with pemphigus who had rituximab as first-line therapy: Follow-up of the ritux 3 trial","volume":"160","author":"Tedbirt","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.25259\/IJDVL_1877_2025\/ref-11","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"10.25259\/IJDVL_1877_2025\/ref-12","doi-asserted-by":"publisher","first-page":"4303","DOI":"10.3390\/ijms21124303","article-title":"CAR-T cell therapy","volume":"21","author":"Ahmad","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.25259\/IJDVL_1877_2025\/ref-13","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.1158\/0008-5472.CAN-14-0697","article-title":"Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors","volume":"74","author":"Nishio","year":"2014","journal-title":"Cancer Res"},{"key":"10.25259\/IJDVL_1877_2025\/ref-14","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1016\/j.ymthe.2023.09.021","article-title":"Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development","volume":"31","author":"Tang","year":"2023","journal-title":"Mol Ther"},{"key":"10.25259\/IJDVL_1877_2025\/ref-15","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","article-title":"Global manufacturing of CAR T cell therapy","volume":"4","author":"Levine","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.25259\/IJDVL_1877_2025\/ref-16","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.jcyt.2019.10.005","article-title":"Autologous cryopreserved leukapheresis cellular material for chimeric antigen receptor-T cell manufacture","volume":"21","author":"Tyagarajan","year":"2019","journal-title":"Cytotherapy"},{"key":"10.25259\/IJDVL_1877_2025\/ref-17","doi-asserted-by":"publisher","first-page":"104889","DOI":"10.1016\/j.cryobiol.2024.104889","article-title":"Cryopreserved leukapheresis material can be transferred from controlled rate freezers to ultracold storage at warmer temperatures without affecting downstream CAR-T cell culture performance and in-vitro functionality","volume":"115","author":"Wei","year":"2024","journal-title":"Cryobiology"},{"key":"10.25259\/IJDVL_1877_2025\/ref-18","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2450\/BloodTransfus.542","article-title":"Advantages of high cell concentration prior to cryopreservation of initial leukapheresis in CAR-T cell therapy","volume":"22","author":"Carbonell","year":"2024","journal-title":"Blood Transfus"},{"key":"10.25259\/IJDVL_1877_2025\/ref-19","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.tips.2024.07.005","article-title":"Frontiers in CAR-T cell therapy for autoimmune diseases","volume":"45","author":"Li","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"10.25259\/IJDVL_1877_2025\/ref-20","doi-asserted-by":"publisher","first-page":"1461102","DOI":"10.3389\/fimmu.2024.1461102","article-title":"CAR immunotherapy in autoimmune diseases: Promises and challenges","volume":"15","author":"Yu","year":"2024","journal-title":"Front Immunol"},{"key":"10.25259\/IJDVL_1877_2025\/ref-21","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"key":"10.25259\/IJDVL_1877_2025\/ref-22","doi-asserted-by":"publisher","first-page":"152786","DOI":"10.1016\/j.semarthrit.2025.152786","article-title":"CAR T-cell therapy in SLE: A systematic review","volume":"74","author":"Nordmann-Gomes","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"10.25259\/IJDVL_1877_2025\/ref-23","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.25259\/IJDVL_1877_2025\/ref-24","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - A case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.25259\/IJDVL_1877_2025\/ref-25","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1016\/S2665-9913(24)00282-0","article-title":"CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: A case series","volume":"7","author":"Auth","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"10.25259\/IJDVL_1877_2025\/ref-26","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-Targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"key":"10.25259\/IJDVL_1877_2025\/ref-27","doi-asserted-by":"publisher","first-page":"100676","DOI":"10.1016\/j.medj.2025.100676","article-title":"CD19 CAR-T cell therapy in a pediatric patient with MDA5+ dermatomyositis and rapidly progressive interstitial lung disease","volume":"6","author":"Par\u00eds-Mu\u00f1oz","year":"2025","journal-title":"Med"},{"key":"10.25259\/IJDVL_1877_2025\/ref-28","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/art.42933","article-title":"Autologous CD19-targeting CAR T cells in a patient with refractory juvenile dermatomyositis","volume":"76","author":"Nicolai","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.25259\/IJDVL_1877_2025\/ref-30","doi-asserted-by":"publisher","first-page":"e92021","DOI":"10.1172\/jci.insight.92021","article-title":"Setting the target for pemphigus vulgaris therapy","volume":"2","author":"Ellebrecht","year":"2017","journal-title":"JCI Insight"},{"key":"10.25259\/IJDVL_1877_2025\/ref-31","doi-asserted-by":"publisher","first-page":"6317","DOI":"10.1172\/JCI138416","article-title":"Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris","volume":"130","author":"Lee","year":"2020","journal-title":"J Clin Invest"},{"key":"10.25259\/IJDVL_1877_2025\/ref-32","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/ajh.26301","article-title":"Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed\/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1 and TRANSCEND trials","volume":"96","author":"Westin","year":"2021","journal-title":"Am J Hematol"},{"key":"10.25259\/IJDVL_1877_2025\/ref-33","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.25259\/IJDVL_1877_2025\/ref-34","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/1744666X.2019.1629904","article-title":"Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome","volume":"15","author":"Kotch","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"10.25259\/IJDVL_1877_2025\/ref-35","doi-asserted-by":"publisher","first-page":"634445","DOI":"10.3389\/fonc.2021.634445","article-title":"Immune effector cell associated neurotoxicity (ICANS) in pediatric and young adult patients following chimeric antigen receptor (CAR) T-cell therapy: Can we optimize early diagnosis?","volume":"11","author":"Brown","year":"2021","journal-title":"Front Oncol"},{"key":"10.25259\/IJDVL_1877_2025\/ref-36","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s00277-024-05617-y","article-title":"Modified EASIX scores predict severe CRS\/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy","volume":"103","author":"Zhao","year":"2024","journal-title":"Ann Hematol"},{"key":"10.25259\/IJDVL_1877_2025\/ref-37","doi-asserted-by":"publisher","first-page":"102137","DOI":"10.1016\/j.trim.2024.102137","article-title":"Outcomes with chimeric antigen receptor T-cell therapy in Rheumatological disorders: A systematic review","volume":"87","author":"Zulfiqar","year":"2024","journal-title":"Transpl Immunol"},{"key":"10.25259\/IJDVL_1877_2025\/ref-38","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.3390\/cancers12113445","article-title":"Complications after CD19+ CAR T-Cell Therapy","volume":"12","author":"Penack","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.25259\/IJDVL_1877_2025\/ref-39","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jaad.2016.06.062","article-title":"Evaluating the skin in patients undergoing chimeric antigen receptor modified T-cell therapy","volume":"75","author":"Rubin","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_1877_2025\/ref-40","doi-asserted-by":"publisher","first-page":"581433","DOI":"10.3389\/fimmu.2020.581433","article-title":"Antigen specificity enhances disease control by tregs in vitiligo","volume":"11","author":"Mukhatayev","year":"2020","journal-title":"Front Immunol"},{"key":"10.25259\/IJDVL_1877_2025\/ref-41","doi-asserted-by":"publisher","first-page":"934343","DOI":"10.3389\/fimmu.2022.934343","article-title":"Regulatory CAR-T cells in autoimmune diseases: Progress and current challenges","volume":"13","author":"Riet","year":"2022","journal-title":"Front Immunol"},{"key":"10.25259\/IJDVL_1877_2025\/ref-42","doi-asserted-by":"publisher","first-page":"1529745","DOI":"10.3389\/fimmu.2025.1529745","article-title":"Treatment of pro-B acute lymphoblastic leukemia and severe plaque psoriasis with anti-CD19 CAR T cells: A case report","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"10.25259\/IJDVL_1877_2025\/ref-43","doi-asserted-by":"publisher","first-page":"1418768","DOI":"10.3389\/fimmu.2024.1418768","article-title":"Incidentally cured psoriasis in a patient with refractory\/relapsed diffuse large B-cell lymphoma receiving CD19 CAR-T cell therapy: A case report","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"10.25259\/IJDVL_1877_2025\/ref-44","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/978-1-0716-3862-0_20","article-title":"Generation of anti-HIV CAR-T cells for preclinical research","volume":"2807","author":"Su","year":"2024","journal-title":"Methods Mol Biol"},{"key":"10.25259\/IJDVL_1877_2025\/ref-45","doi-asserted-by":"publisher","first-page":"e150211","DOI":"10.1172\/JCI150211","article-title":"Broadly neutralizing antibody-derived CAR T cells reduce viral reservoir in individuals infected with HIV-1","volume":"131","author":"Liu","year":"2021","journal-title":"J Clin Invest"},{"key":"10.25259\/IJDVL_1877_2025\/ref-46","doi-asserted-by":"publisher","first-page":"200862","DOI":"10.1016\/j.omton.2024.200862","article-title":"TYRP1 directed CAR T cells control tumor progression in preclinical melanoma models","volume":"32","author":"Hackett","year":"2024","journal-title":"Mol Ther Oncol"},{"key":"10.25259\/IJDVL_1877_2025\/ref-47","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/s41467-024-45221-2","article-title":"CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes","volume":"15","author":"Jilani","year":"2024","journal-title":"Nat Commun"},{"key":"10.25259\/IJDVL_1877_2025\/ref-48","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3389\/fonc.2019.00259","article-title":"CAR-based approaches to cutaneous T-cell lymphoma","volume":"9","author":"Scarf\u00f2","year":"2019","journal-title":"Front Oncol"},{"key":"10.25259\/IJDVL_1877_2025\/ref-49","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"10.25259\/IJDVL_1877_2025\/ref-50","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1200\/JCO-24-01933","article-title":"Allogeneic chimeric antigen receptor T-cell products cemacabtagene ansegedleucel\/ALLO-501 in relapsed\/refractory large B-cell lymphoma: Phase I experience from the ALPHA2\/ALPHA clinical studies","volume":"43","author":"Locke","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.25259\/IJDVL_1877_2025\/ref-51","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40164-025-00633-8","article-title":"The clinical landscape of CAR NK cells","volume":"14","author":"J\u00f8rgensen","year":"2025","journal-title":"Exp Hematol Oncol"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/chimeric-antigen-receptor-car-t-cell-therapy-in-dermatology-a-narrative-review\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/chimeric-antigen-receptor-car-t-cell-therapy-in-dermatology-a-narrative-review\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T13:02:09Z","timestamp":1767358929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/chimeric-antigen-receptor-car-t-cell-therapy-in-dermatology-a-narrative-review\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":49,"alternative-id":["10.25259\/IJDVL_1877_2025"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_1877_2025","relation":{},"ISSN":["0973-3922","0378-6323"],"issn-type":[{"value":"0973-3922","type":"electronic"},{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"article-number":"52"}}